Ceftazidime-avibactam in ceftazidime-resistant infections

The Lancet Infectious Diseases

Volumn 16, Issue 9, 2016, Pages 997-

  Raut, Shristi ^a   Adhikari, Bipin ^b  

^a Lumbini Medical College   (Nepal)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CEFTAZIDIME; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG COST; HUMAN; INCOME; LETTER; MIDDLE INCOME COUNTRY; NEPAL; PRIORITY JOURNAL; URINARY TRACT INFECTION; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84999816126     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30194-3     Document Type: Letter

References (5)

1. 1 Carmeli, Y, Armstrong, J, Laud, PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16 (2016), 661–673.
2. 2 Pharmacist's letter/Prescriber's letter. Comparison of carbapenem antibiotics. http://pharmacistsletter.therapeuticresearch.com/pl/ArticlePDF.aspx?cs=&s=PL&dd=231205&segment=77&usg=AFQjCNHsCvEAEbd_y1YxJ0apbKkHca9vKw&sig2=AtOJoYv39dEtDG4CS3P38A&bvm=bv.127984354,d.c2, December 2007 (accessed July 25, 2016).
3. 3 Harald. Avycaz approval and labeling restrictions. Allphase Pharma Consulting, LLC, August 26, 2015. http://allphasepharma.com/dir/2015/08/26/1887/avicaz-approval-and-labeling-restrictions/ (accessed May 29, 2016).
4. 4 Raut, S, Gokhale, S, Adhikari, B, Prevalence of extended spectrum beta-lactamases among Escherichia coli and Klebsiella spp isolates in Manipal Teaching Hospital, Pokhara, Nepal. J Microbiol Infect Dis 5 (2015), 69–75.
5. 5 Raut, S, Adhikari, B, Global leadership against antimicrobial resistance ought to include developing countries. Lancet Infect Dis, 16, 2016, 775.